Estimation of the prognostic value of plasma ADAMTS-13 in covid-19 patients

Abstract

Coronavirus disease of 2019 (COVID-19) is the clinical manifestation of the respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While primarily recognized as a respiratory disease, COVID-19 is now recognized as a systemic illness impacting multiple organ systems. One defining clinical feature of COVID-19 has been the high incidence of thrombotic events. The underlying processes and risk factors for the occurrence of thrombotic events in COVID-19remain inadequately understood. Cumulative findings of microvascular thrombosis have raised the attention to vWF and its protease ADAMTS-13. The current study aimed to measure the plasma level of ADAMTS-13 in covid-19 patients and to correlate its level with the prognosis of the disease and the clinical outcome of the patients. This study included 80 patients proved to have covid-19 by PCR who were subjected to measurement of ADAMTS-13 by ELISA. Plasma levels of ADAMTS-13 revealed significant low concentrations in the majority of patients (73.75%). ADAMTS-13 showed good diagnostic power in included patients with sensitivity 60% and specificity 100%. Patients presented with cough and chest pain showed significant low concentrations of ADAMTS-13. References